Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Summary on Jun 27, 2018

June 27, 2018 - By Edith Ladford

Seattle Genetics, Inc. (NASDAQ:SGEN) Corporate Logo
During Q1 2018 the big money sentiment increased to 1.61. That’s change of 0.38, from 2017Q4’s 1.23. 24 investors sold all, 53 reduced holdings as Seattle Genetics, Inc. ratio increased. 93 rose positions while 31 funds amassed positions. Funds hold 159.52 million shares thus 12.47% more from 2017Q4’s 141.83 million shares.
Jfs Wealth Advisors Limited Liability Corporation holds 0% or 275 shs. Us Bank & Trust De has invested 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). Amundi Pioneer Asset Inc holds 0% of its capital in Seattle Genetics, Inc. (NASDAQ:SGEN) for 21,523 shs. Renaissance Techs Limited Liability Company holds 0.01% or 239,313 shs in its capital. Trexquant Investment Ltd Partnership accumulated 0.08% or 22,406 shs. Aqr Mngmt Limited reported 0% in Seattle Genetics, Inc. (NASDAQ:SGEN). Credit Suisse Ag has 0.01% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 115,478 shs. Moreover, Asset Management One Communication Ltd has 0.03% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 215,851 shs. Amp Limited reported 32,933 shs. Invesco Limited owns 315,205 shs for 0.01% of their capital. Tower Rech Capital Limited Liability (Trc) has 7,006 shs for 0.03% of their capital. Point72 Asia (Hong Kong) Limited holds 0.04% of its capital in Seattle Genetics, Inc. (NASDAQ:SGEN) for 1,558 shs. Nomura Asset Management Communications Limited has invested 0.01% in Seattle Genetics, Inc. (NASDAQ:SGEN). Bancorporation Of Mellon Corp reported 469,559 shs stake. Wellington Mgmt Gp Llp accumulated 0.12% or 9.90 million shs.

Seattle Genetics, Inc. had 12 insider sales and 3 buys since January 11, 2018. This’s net activity of $266.95 million. On Friday, May 4 460,651 shs were bought by BAKER BROS. ADVISORS LP, worth $24.57 million. Cline Darren S sold 4,000 shs worth $215,238. DRACHMAN JONATHAN G sold $552,452 worth of stock. $292,365 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) was sold by HIMES VAUGHN B.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

A total of 8 analysts rate Seattle Genetics (NASDAQ:SGEN) as follows: 7 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 88% are bullish. (NASDAQ:SGEN) has 12 ratings reports on Jun 27, 2018 according to StockzIntelligence. On Thursday, February 1 the company was maintained by H.C. Wainwright. On Wednesday, February 7 the company was maintained by Needham. In Wednesday, January 31 report RBC Capital Markets maintained it with “Buy” rating and $71.0 target. On Wednesday, February 7 the stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Hold” rating given by SunTrust. On Tuesday, March 20 the stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Buy” rating by RBC Capital Markets. On Wednesday, March 21 the firm has “Overweight” rating by Morgan Stanley given. In Wednesday, February 7 report Bank of America maintained the stock with “Neutral” rating. On Monday, June 11 the firm earned “Buy” rating by SunTrust. On Friday, April 27 H.C. Wainwright maintained Seattle Genetics, Inc. (NASDAQ:SGEN) rating. H.C. Wainwright has “Buy” rating and $7700 target. On Wednesday, February 14 JP Morgan upgraded Seattle Genetics, Inc. (NASDAQ:SGEN) to “Overweight” rating. Listed here are Seattle Genetics, Inc. (NASDAQ:SGEN) PTs and latest ratings.

11/06/2018 Broker: SunTrust Rating: Buy Upgrade
27/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0000 Maintain
21/03/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $69 New Target: $67 Maintain
20/03/2018 Broker: RBC Capital Markets Rating: Buy New Target: $73.0 Maintain
14/02/2018 Broker: J.P. Morgan Rating: Buy New Target: $66.0 Upgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Old Target: $60 Upgrade
07/02/2018 Broker: Needham Rating: Buy New Target: $74.0 Maintain
07/02/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $70 New Target: $68 Maintain
07/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0 Maintain
07/02/2018 Broker: SunTrust Rating: Hold New Target: $60.0 Maintain

SGEN is reaching $65.39 during the last trading session, after decreased 0.43%.Currently Seattle Genetics, Inc. is downtrending after 15.50% change in last June 27, 2017. SGEN has also 296,186 shares volume. SGEN underperformed the S&P500 by 28.07%.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide.The firm is worth $10.35 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.Last it reported negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

A couple more Seattle Genetics, Inc. (NASDAQ:SGEN) news were released by: Seekingalpha.com which released on June 13, 2018 “Immunomedics: Short-Term Risk, Long-Term Opportunity”, also Streetinsider.com on June 11, 2018 released “SunTrust Robinson Humphrey Upgrades Seattle Genetics (SGEN) to Buy; Improving Prospects For Adcetris In 1L HL”, the next Nasdaq.com is “Analysis: Positioning to Benefit within The Manitowoc, Omeros, Catabasis Pharmaceuticals, Zayo Group, Covanta …” on June 26, 2018. Seekingalpha.com has article titled “Premarket analyst action – healthcare”.

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: